KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Inventory (2016 - 2025)

Biogen (BIIB) has 17 years of Inventory data on record, last reported at $2.2 billion in Q4 2025.

  • For Q4 2025, Inventory fell 11.88% year-over-year to $2.2 billion; the TTM value through Dec 2025 reached $2.2 billion, down 11.88%, while the annual FY2025 figure was $2.2 billion, 11.88% down from the prior year.
  • Inventory reached $2.2 billion in Q4 2025 per BIIB's latest filing, down from $2.2 billion in the prior quarter.
  • Across five years, Inventory topped out at $3.0 billion in Q3 2023 and bottomed at $1.2 billion in Q1 2021.
  • Average Inventory over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2022.
  • Peak YoY movement for Inventory: surged 116.9% in 2023, then fell 17.21% in 2024.
  • A 5-year view of Inventory shows it stood at $1.4 billion in 2021, then decreased by 0.53% to $1.3 billion in 2022, then soared by 87.99% to $2.5 billion in 2023, then decreased by 2.65% to $2.5 billion in 2024, then fell by 11.88% to $2.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $2.2 billion in Q4 2025, $2.2 billion in Q3 2025, and $2.3 billion in Q2 2025.